Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 18, 2008
app pub date -
Jun 28, 2006
filing date -
Jun 28, 2005
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
CXCR3 inhibitors of formula are disclosed. Inhibition of CXCR3 activation is useful for treating disorders resulting from CXCR3-associated T-cell mediated function, such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and diabetes, as well as in the prevention of allograft rejection. N-ethyl-1,4-diazepane-1-carboxamides in which R.sup.1 is substituted or unsubstituted arylalkyl and R.sup.3 is substituted or unsubstituted aryl are particularly preferred.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully